/wp-content/uploads/logo-300x63.png
0
0
eallison
/wp-content/uploads/logo-300x63.png
eallison2023-11-02 11:10:052024-03-06 14:42:04Synthekine Presents Preclinical Data at SITC 38th Annual Meeting Demonstrating its IL-12 Partial Agonist, STK-026, Significantly Expands Therapeutic Window
/wp-content/uploads/logo-300x63.png
0
0
David Anderson
/wp-content/uploads/logo-300x63.png
David Anderson2023-09-27 10:40:252023-09-27 17:44:30First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors
/wp-content/uploads/logo-300x63.png
0
0
David Anderson
/wp-content/uploads/logo-300x63.png
David Anderson2023-07-26 13:50:052023-07-26 13:51:07Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies
/wp-content/uploads/logo-300x63.png
0
0
David Anderson
/wp-content/uploads/logo-300x63.png
David Anderson2023-04-11 17:22:132023-04-11 17:22:13Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs
/wp-content/uploads/logo-300x63.png
0
0
David Anderson
/wp-content/uploads/logo-300x63.png
David Anderson2023-01-05 17:26:342023-01-05 19:12:40Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
Scroll to top
